Winstgevend schreef op 8 januari 2019 12:04:
Omdat de Pharming website zwaar achterloopt met de huidige stand van zaken
heb ik zelf maar even het meest actuele op een rijtje gezet en ingevuld.
Pharming Group N.V.
Estimated (first three) clinical trial timeframesBased on two clinical trials per indication without priority-status
Delayed Graft Function: 7.500 cases in the USA- Size: 20.000 kidney-transplants in the USA
- Start of Phase II Clinical trial in
Q1 2019- Start of Phase III Clinical trial in Q3 2020
- Request for FDA-Approval in Q3 2021
- Possible DFA-Approval in Q3 2022
- Marketing startup by Q1 2023
Contrast Induced Nephropathy: 1 million cases in the USA - Size: 192 million treatments per year Globaly
-
Start of Phase III Clinical trial in Q1 2019 - Request for FDA-Approval in Q1 2021
- Possible DFA-Approval in Q1 2022
- Marketing startup by Q3 2022
Pre-eclampsia: 250.000 cases in the USA- Size: 3.86 million births in the USA
- Start of Phase II Clinical trial in
Q1 2019- Start of Phase III Clinical trial in Q3 2020
- Request for FDA-Approval in Q1 2022
- Possible DFA-Approval in Q1 2023
- Marketing startup by Q3 2023